Related Experiment Videos
Novel biomaterials for bisphosphonate delivery
Solen Josse1, Corinne Faucheux, A Soueidan
1Faculté des Sciences et des Techniques, Laboratoire de Synthèse Organique, University of Nantes, UMR CNRS 6513 and FR CNRS 2465, 2 Rue de la Houssinière , BP92208, 44322 Nantes Cedex 3, France.
Biomaterials
|December 4, 2004
Summary
Zoledronate chemically binds to calcium phosphate compounds, forming crystals or adsorbing to surfaces. These materials effectively release Zoledronate, inhibiting osteoclast activity in vitro.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Bone Biology
Background:
- Bisphosphonates, such as Zoledronate, are crucial in treating bone diseases.
- Calcium phosphate (CaP) compounds are widely used in bone regeneration and biomaterials.
- Understanding the interaction between Zoledronate and CaP is key for developing effective bone therapies.
Purpose of the Study:
- To investigate the chemical association of Zoledronate with various calcium phosphate compounds.
- To elucidate the different modes of Zoledronate association based on CaP composition and Zoledronate concentration.
- To evaluate the in vitro efficacy of Zoledronate-loaded CaP materials in inhibiting osteoclast activity.
Main Methods:
- Preparation of CaP powders with controlled granulometry.
- Suspension of CaP powders in aqueous Zoledronate solutions of varying concentrations.
- (31)P NMR spectroscopy for analyzing Zoledronate-CaP interactions.
- In vitro bone resorption model to assess osteoclast inhibition.
Main Results:
- Two distinct Zoledronate association modes were observed, dependent on CaP type and Zoledronate concentration.
- beta-tricalcium phosphate (beta-TCP) and BCPs facilitated the formation of Zoledronate-containing crystals.
- Calcium-deficient apatites (CDAs) showed chemisorption at low Zoledronate concentrations (<0.05 mol L(-1)) and crystalline complex formation at higher concentrations (>0.05 mol L(-1)).
- The developed materials demonstrated Zoledronate release capable of inhibiting osteoclastic activity.
Conclusions:
- Zoledronate can be chemically associated with diverse CaP materials through distinct mechanisms.
- The nature of the CaP support and Zoledronate concentration dictate the association mode and resulting material properties.
- These Zoledronate-CaP composites show promise as effective agents for inhibiting bone resorption.